AlphaMadera's AlphaVal page computes Bio-Rad Laboratories, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag BIO as undervalued, fairly valued, or overvalued.

What is Bio-Rad Laboratories, Inc.'s fair value?

Fair value for BIO is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value BIO?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from BIO's most recent reported fundamentals.

BIO - Bio-Rad Laboratories, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $321.67 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Strong

Trading 60.9% below fair value

Current Price $298.76

Bear Case $610.86 104.5% upside ($610.86 - $298.76) / $298.76 = 104.5% $58.27 × 12x P/E

Fair Value $763.57 155.6% upside ($763.57 - $298.76) / $298.76 = 155.6% $58.27 × 15x P/E

Bull Case $916.29 206.7% upside ($916.29 - $298.76) / $298.76 = 206.7% $58.27 × 18x P/E

Adjust Assumptions

P/E Multiple

15.0x

Adjusted EPS

58.27$

Key Value Driver

Normalized P/E multiple (15x base case)

Implied Market Multiple 5.1x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $321.67 from 14 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $763.57 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 109%. Check what costs are being left out of the adjusted number.

ℹ Wall Street's average price target is $321.67 (from 14 analysts). Our estimate is 172% above the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples